Catalyst Pharmaceuticals Q1 Adj $0.38 Beats $0.17 Estimate, Sales $98.51M Beat $98.13M Estimate
Portfolio Pulse from Benzinga Newsdesk
Catalyst Pharmaceuticals (NASDAQ:CPRX) reported Q1 adjusted earnings of $0.38 per share, surpassing the $0.17 estimate, a 123.53% beat. Despite a 7.32% decrease from last year's $0.41, sales rose to $98.51M, slightly above the $98.13M forecast, marking a 15.40% year-over-year increase.
May 08, 2024 | 8:22 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Catalyst Pharmaceuticals reported a significant beat on Q1 earnings and sales, with earnings per share at $0.38 against a $0.17 estimate and sales reaching $98.51M, exceeding expectations.
The substantial beat on both earnings per share and sales estimates for Catalyst Pharmaceuticals indicates a strong financial performance, likely leading to positive investor sentiment and potential short-term stock price appreciation.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100